# Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma

> **NCT01399372** · PHASE2 · COMPLETED · sponsor: **Radiation Therapy Oncology Group** · enrollment: 91 (actual)

## Conditions studied

- Chemotherapeutic Agent Toxicity
- Cognitive/Functional Effects
- Lymphoma
- Neurotoxicity
- Radiation Toxicity

## Interventions

- **BIOLOGICAL:** Rituximab
- **DRUG:** Cytarabine
- **DRUG:** Methotrexate
- **DRUG:** Procarbazine
- **DRUG:** Vincristine
- **RADIATION:** low-dose whole-brain radiation therapy

## Key facts

- **NCT ID:** NCT01399372
- **Lead sponsor:** Radiation Therapy Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2020-03-19
- **Final completion:** 2022-05-20
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2023-07-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01399372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01399372, "Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01399372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*